Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making

Expert Review of Hematology

Volumn 10, Issue 6, 2017, Pages 563-574

  Tomlinson, Benjamin ^a   Lazarus, Hillard M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Acute myeloid leukemia; core binding factor leukemia; minimal residual disease; multi color flow cytometry; NPM1; quantitative PCR; WT1

Indexed keywords

CD135 ANTIGEN; CORE BINDING FACTOR BETA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN; ONCOPROTEIN;

ACUTE MYELOID LEUKEMIA; CANCER THERAPY; DISEASE ASSESSMENT; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; FLOW CYTOMETRY; FOLLOW UP; FUSION GENE; GENE MUTATION; GENE OVEREXPRESSION; HEALTH CARE QUALITY; HUMAN; IMMUNOPHENOTYPING; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; NEXT GENERATION SEQUENCING; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; BLOOD; DECISION MAKING; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM, RESIDUAL; PHYSIOLOGIC MONITORING; PROCEDURES; VASCULARIZATION;

DECISION MAKING; FLOW CYTOMETRY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 85020225914     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1080/17474086.2017.1326811     Document Type: Review

References (91)

1. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
2. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New England J Med. 2013;369:111–121.
3. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–4649.
4. Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol. 1988;6:583–587. Epub 1988/04/01.
5. Freireich EJ, Wiernik PH, Steensma DP., The leukemias:a half-century of discovery. J Clin Oncol. 2014;32:3463–3469. Epub 2014/09/04.
6. Goldman JM, Gale RP., What does MRD in leukemia really mean? Leukemia. 2014;28:1131. Epub 2013/10/31.
7. Logan AC, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20:1307–1313. Epub 2014/04/29.
8. Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL:a report from Children’s Oncology Group study AALL0232. Blood. 2015;126:964–971. Epub 2015/07/01.
9. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials:proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010;24:521–535. Epub 2009/12/25.
10. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27:3650–3658. Epub 2009/06/10.
11. Santamaria C, Chillon MC, Fernandez C, et al. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica. 2007;92:315–322. Epub 2007/03/07.
12. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia:an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758–3765. Epub 2010/08/04.
13. Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2010;95:224–231. Epub 2009/10/17.
14. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17:2401–2409. Epub 2003/10/03.
15. Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood. 1998;91:3357–3365. Epub 1998/05/23.
16. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437–4444. Epub 2008/08/22.
17. Jabbour E, Kantarjian H, O’Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541–4546.
18. Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol. 2009;131:16–26. Epub 2008/12/20.
19. Kern W, Schoch C, Haferlach T, et al. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol. 2005;56:283–309. Epub 2005/10/11.
20. Voskova D, Schoch C, Schnittger S, et al. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse:comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytom B Clin Cytom. 2004;62:25–38. Epub 2004/10/07.
21. Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000;96:3948–3952. Epub 2000/11/23.
22. Al-Mawali A, Gillis D, Lewis I. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytom B Clin Cytom. 2009;76:91–101. Epub 2008/08/30.
23. Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia. 2006;20:1783–1789. Epub 2006/07/14.
24. Köhnke T, Sauter D, Ringel K, et al. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia. 2015;29:377–386. Epub 2014/06/11.
25. Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123–4131. Epub 2013/09/26.• Study suggesting clinically relevant cutoffs and time points for MFC monitoring of MRD in AML.
26. Terwijn M, Van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia:data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–3897. Epub 2013/09/26.• Study suggesting clinically relevant cutoffs and time points for MFC monitoring of MRD in AML.
27. Yin JA, O’Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse:results of the United Kingdom MRC AML-15 trial. Blood. 2012;120:2826–2835. Epub 2012/08/10.•• Study suggesting clinically relevant cutoffs and time points for quantitative PCR in core binding factor AML.
28. Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010;28:3724–3729. Epub 2010/07/14.•• Study suggesting clinically relevant cutoffs and time points for quantitative PCR in core binding factor AML.
29. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121:2213–2223. Epub 2013/01/17.
30. Scholl C, Schlenk RF, Eiwen K, et al. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica. 2005;90:1626–1634. Epub 2005/12/07.
31. Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–433.• One of the largest clinical trials to evaluate NPM1 quantitative PCR, suggesting that PCR negativity after two cycles of induction may be more predictive for outcome that standard risk categories.
32. Krönke J, Schlenk RF, Jensen K-O, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia:a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29:2709–2716. Epub 2011/05/11.• Large data set suggesting clinically relevant cutoffs and time points for NPM1 quantitative PCR.
33. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia:a European LeukemiaNet study. J Clin Oncol. 2009;27:5195–5201. Epub 2009/09/16.• Largest trial evaluating WT1 overexpression as a tool for MRD monitoring and defines potentially relevant clinical endpoints.
34. Trka J, Kalinova M, Hrusak O, et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML:prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia. 2002;16:1381–1389. Epub 2002/07/03.
35. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia:results of the AML02 multicentre trial. Lancet Oncol. 2010;11:543–552. Epub 2010/05/11.•• Example of adaptive therapy trial in pediatric AML–a potential model for development of trials for adult AML.
36. Maurillo L, Buccisano F, Spagnoli A, et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica. 2007;92:605–611. Epub 2007/05/10.
37. Gabert J, Beillard E, Van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17:2318–2357. Epub 2003/10/17.
38. Elmaagacli AH, Beelen DW, Kroll M, et al. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 1998;21:159–166. Epub 1998/03/07.
39. Martinelli G, Buonamici S, Visani G, et al. Molecular monitoring of acute myeloid leukemia associated with inv(16):threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely. Leukemia. 2003;17:650–651; author reply 1–2. Epub 2003/03/21.
40. Guerrasio A, Pilatrino C, De Micheli D, et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia. 2002;16:1176–1181. Epub 2002/06/01.
41. Pigazzi M, Manara E, Buldini B, et al. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica. 2015;100:e99–101. Epub 2014/12/07.
42. Zhang L, Cao Z, Ruan M, et al. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia. Pediatr Blood Cancer. 2014;61:1761–1766. Epub 2014/06/13.
43. Willekens C, Blanchet O, Renneville A, et al. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia:results of the French CBF-2006 trial. Haematologica. 2016;101:328–335. Epub 2015/12/05.
44. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115:198–205. Epub 2009/11/11.
45. Krumbholz M, Jung R, Bradtke J, et al. Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific MLL-FNBP1 fusion gene. Leuk Lymphoma. 2015;56:793–796. Epub 2014/06/03.
46. Takatsuki H, Yufu Y, Tachikawa Y, et al. Monitoring minimal residual disease in patients with MLL-AF6 fusion transcript-positive acute myeloid leukemia following allogeneic bone marrow transplantation. Int J Hematol. 2002;75:298–301. Epub 2002/05/10.
47. Cuneo A, Bigoni R, Roberti MG, et al. Detection and monitoring of trisomy 8 by fluorescence in situ hybridization in acute myeloid leukemia:a multicentric study. Haematologica. 1998;83:21–26. Epub 1998/05/16.
48. Schmidt HH, Pirc-Danoewinata H, Linkesch W, et al. inv(3)(q21q26) in AML/MDS:monitoring of the malignant clone with interphase FISH. Haematologica. 2003;88:Ecr38. Epub 2003/12/23.
49. Porta G, Maserati E, Mattarucchi E, et al. Monosomy 7 in myeloid malignancies:parental origin and monitoring by real-time quantitative PCR. Leukemia. 2007;21:1833–1835. Epub 2007/04/27.
50. Gregory TK, Wald D, Chen Y, et al. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009;2:23.
51. Dvorakova D, Racil Z, Jeziskova I, et al. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations. Am J Hematol. 2010;85:926–929. Epub 2010/10/29.
52. Abdelhamid E, Preudhomme C, Helevaut N, et al. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res. 2012;36:316–323. Epub 2011/12/02.
53. Schiller J, Praulich I, Krings Rocha C, et al. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia. Eur J Haematol. 2012;89:53–62. Epub 2012/03/31.
54. Palmisano M, Grafone T, Ottaviani E, et al. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Haematologica. 2007;92:1268–1269. Epub 2007/09/05.
55. Tang J-L, Hou H-A, Chen C-Y, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia:prognostic implication and interaction with other gene alterations. Blood. 2009;114:5352–5361.
56. Kohlmann A, Nadarajah N, Alpermann T, et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia. 2014;28:129–137. Epub 2013/08/21.
57. Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients:a study by the Acute Leukemia French Association. Oncotarget. 2015;6:42345–42353. Epub 2015/10/22.• Early article evaluating IDH1, IDH2, and DNMT3A as potential markers for MRD. Highlights the need to understand dynamics very well.
58. Jeziskova I, Razga F, Toskova M, et al. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene. Leuk Lymphoma. 2013;54:867–870. Epub 2012/09/07.
59. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol. 2004;112:79–84. Epub 2004/06/05.
60. Sakamoto Y, Mariya Y, Sasaki S, et al. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia. Tohoku J Exp Med. 2009;219:169–176. Epub 2009/09/25.
61. Yang L, Han Y, Suarez Saiz F, et al. A tumor suppressor and oncogene:the WT1 story. Leukemia. 2007;21:868–876. Epub 2007/03/16.
62. Kitamura K, Nishiyama T, Ishiyama K, et al. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia:a comparison with expression of WT1 mRNA in peripheral blood. Int J Hematol. 2016;103:53–62. Epub 2015/11/02.
63. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071–3079. Epub 1994/11/01.
64. Østergaard M, Olesen LH, Hasle H, et al. WT1 gene expression:an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol. 2004;125:590–600. Epub 2004/05/19.
65. Buckley SA, Appelbaum FR, Walter RB. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant. 2013;48:630–641. Epub 2012/07/25.
66. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:1190–1197.
67. Leung W, Pui C-H, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120:468–472.
68. Venditti A, Maurillo L, Buccisano F, et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia. 2003;17:2178–2182. Epub 2003/10/25.
69. Wang Y, Wu D-P, Liu Q-F, et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood. 2014;124:1880–1886. Epub 2014/08/02.
70. Miyazaki T, Fujita H, Fujimaki K, et al. Clinical significance of minimal residual disease detected by multidimensional flow cytometry:serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leuk Res. 2012;36:998–1003. Epub 2012/05/04.
71. Wertheim GB, Bagg A. Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes. Expert Rev Mol Diagn. 2011;11:361–366. Epub 2011/05/07.
72. Van der Reijden BA, Simons A, Luiten E, et al. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion. Br J Haematol. 2002;118:411–418. Epub 2002/07/26.
73. Bacher U, Badbaran A, Fehse B, et al. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol. 2009;37:135–142. Epub 2008/12/23.
74. Dominietto A, Pozzi S, Miglino M, et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood. 2007;109:5063–5064.
75. Pozzi S, Geroldi S, Tedone E, et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia:predictive role of WT1 expression. Br J Haematol. 2013;160:503–509. Epub 2013/01/09.
76. Ouyang J, Goswami M, Peng J, et al. Comparison of multiparameter flow cytometry immunophenotypic analysis and quantitative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia. Am J Clin Pathol. 2016;145:769–777. Epub 2016/06/15.
77. Pløen GG, Nederby L, Guldberg P, et al. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol. 2014;167:478–486. Epub 2014/11/06.
78. Jeziskova I, Musilova M, Culen M, et al. Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML. Int J Hematol. 2015;102:553–557. Epub 2015/08/21.
79. Papadaki C, Dufour A, Seibl M, et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR:clonal evolution is a limiting factor. Br J Haematol. 2009;144:517–523. Epub 2008/12/06.
80. Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314:811–822. Epub 2015/08/26.
81. Thol F, Kölking B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer. 2012;51:689–695. Epub 2012/03/29.
82. Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq:applicability for diagnostics and disease monitoring. Haematologica. 2014;99:465–473. Epub 2013/10/22.
83. Hokland P, Ommen HB, Mulé MP, et al. Advancing the minimal residual disease concept in acute myeloid leukemia. Semin Hematol. 2015;52:184–192. Epub 2015/06/27.
84. Bibault J-E, Figeac M, Hélevaut N, et al. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget. 2015;6:22812–22821. Epub 2015/06/17.
85. Vanderhoek M, Juckett MB, Perlman SB, et al. Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging. Leuk Res. 2011;35:310–316. Epub 2010/09/14.
86. Mattison RJ, Luger SM, Lazarus HM. New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia. Curr Opin Hematol. 2013;20:93–99. Epub 2013/01/19.
87. Sperr WR, Mitterbauer M, Mitterbauer G, et al. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res. 2005;11:6536–6543. Epub 2005/09/17.
88. DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013;121:4917–4924. Epub 2013/05/04.
89. Esteve J, Escoda L, Martin G, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99):benefit of an early intervention. Leukemia. 2007;21:446–452.
90. Grimwade D, Jovanovic JV, Hills RK. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia? Best Pract Res Clin Haematol. 2014;27:53–61. Epub 2014/06/08.
91. Jordan CT. The leukemic stem cell. Best Pract Res Clin Haematol. 2007;20:13–18.